Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-010830

CHIEF SCIENTIFIC OFFICER sold 30,000 shares at $25.04 ($751,332)

  • CHIEF SCIENTIFIC OFFICER acquired 30,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER 2024-04-11 Option exercise 10b5-1 +30,000 $1.12 $33,600 30,000 D: show line 1 in the form
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER 2024-04-11 Sale 10b5-1 −30,000 $25.04 $751,332 0 D: show line 2 in the form
Open-market sales · 30,000 sh · avg $25.04 · $751,332

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER 2024-04-11 Option exercise · Stock Option (right to buy) 10b5-1 −30,000 230,550 D: show line 3 in the form
Loading xslF345X05/form4-04152024_110409.xml…